Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies

BACKGROUND Lipedema is a chronic disorder characterized by disproportionate accumulation of subcutaneous fat, most commonly affecting the extremities, and is associated with pain, inflammation, and fibrosis. Effective medical therapies are lacking, and liposuction remains the primary treatment. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate metabolic and anti-inflammatory effects, but their role in lipedema remains unclear OBJECTIVE To evaluate the potential role of GLP-1–based therapies in the management of lipedema. METHODS A literature search of peer-reviewed articles published through March 2026 was conducted using PubMed. Search terms included “lipedema and GLP-1” and related combinations of GLP-1 RAs, tirzepatide, inflammation, and insulin resistance. Relevant studies in lipedema, obesity, and fibroinflammatory conditions were included. RESULTS Thirteen publications were identified. Two specifically evaluated GLP-1 RAs in lipedema, with only 1 providing direct patient evidence. A small uncontrolled case series of 5 patients treated with exenatide reported improvements in pain and limb volume. Translational evidence suggests that GLP-1 RAs, particularly tirzepatide, may influence inflammatory and fibrotic pathways relevant to lipedema. CONCLUSION To date, GLP-1 RAs have not been proven to have direct effects on lipedema progression. However, given their known role in weight reduction and metabolic improvement, they may provide benefit as adjunctive therapies.